UK-based specialty drugmaker Norgine says that it has begun exporting Moviprep (NRL994) from its manufacturing site at Hengoed, in Glamorgan, south Wales, to the USA. The product, which is indicated for bowel cleansing prior to colonoscopy, was approved by the US Food and Drug Administration last summer.
Norgine added that USA-based drugmaker Salix Pharmaceuticals licensed exclusive marketing rights for the product in its home territory in late 2005 (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze